Overview
- In September the Ontario Superior Court quashed the province’s initial refusal, ordered an expedited reconsideration and warned that patient Alex Shved would likely die without the requested TIL therapy.
- On Thursday the government amended regulations to limit out‑of‑country funding to treatments already funded in Ontario or temporarily unavailable in province.
- Following the regulatory change OHIP denied Shved’s application for a third time and the health minister said the province may appeal the court ruling or seek a individually negotiated resolution.
- Officials and OHIP previously said routinely funding unapproved foreign treatments would undercut manufacturers’ incentives to participate in Canada’s review and pricing process, a reason cited in successive denials.
- Health Canada approved a commercial TIL product called lifileucel in August 2025 but it is not available in Canada outside trials and reported per‑patient costs are roughly US$515,000–US$600,000, raising cost and precedent concerns for provincial drug plans.